<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="107606">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01940263</url>
  </required_header>
  <id_info>
    <org_study_id>SGU-02</org_study_id>
    <secondary_id>81372994</secondary_id>
    <nct_id>NCT01940263</nct_id>
  </id_info>
  <brief_title>Purified Anthocyanin and Nonalcoholic Fatty Liver Disease</brief_title>
  <official_title>Effects of Purified Anthocyanin on Oxidative and Inflammatory Markers in Subjects With Nonalcoholic Fatty Liver Disease: A Randomized, Double-Blinded, Placebo-Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shaoguan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shaoguan University</source>
  <oversight_info>
    <authority>China: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oxidative stress and inflammation are involved in the pathogenesis of non-alcoholic fatty
      liver disease (NAFLD). Anthocyanins from different plant foods have been shown to improve
      features of experimental NASH, such as oxidative stress, dyslipidemia, liver steatosis, and
      inflammation in rodents. The purpose of this study is to investigate whether purified
      anthocyanin supplementation beneficially alters oxidative, inflammatory, and apoptotic
      biomarkers in adults with features of NAFLD.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 0</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Biomarkers related to oxidative stress</measure>
    <time_frame>Twelve weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>plasma total antioxidant capacity; plasma levels of protein carbonyl groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biomarkers related to inflammation</measure>
    <time_frame>Twelve weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>tumor necrosis factor alpha; interleukin-8; high sensitive C-reactive protein</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Nonalcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo 320 mg daily for twelve weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anthocyanin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: MEDOX (natural purified anthocyanin) anthocyanin 320 mg daily for twelve weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Anthocyanin</intervention_name>
    <arm_group_label>Anthocyanin</arm_group_label>
    <other_name>MEDOX (natural purified anthocyanin)</other_name>
    <other_name>http://www.medox.no/english</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI [body weight divided by height squared (in kg/m2)] &gt; 23,

          -  lack of excessive alcohol ingestion confirmed by careful questioning by the primary
             physician and dietitians (consumption of less than 70 g alcohol in female and 140 g
             in male per week), and

          -  the presence of two of the three following diagnostic criteria of the fatty liver
             disease: increased hepatic echogenicity compared to the spleen or the kidneys,
             blurring of liver vasculature and deep attenuation of the ultrasonographic signal.

        Exclusion Criteria:

          -  overuse of alcohol,

          -  viral hepatitis,

          -  type 1 or 2 diabetes,

          -  gastrointestinal or connective diseases,

          -  chronic pancreatitis,

          -  liver cirrhosis,

          -  kidney stones, or renal failure;

          -  use of acetyl-salicylic acid or other antiplatelet drugs, statins of fibrates, oral
             hypoglycemic drugs, nitrates, nonsteroidal antiinflammatory drugs, corticosteroids,
             or drugs interfering with coagulation;

          -  supplementation with vitamins or antioxidants
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wenhua Ling, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Honghui Guo, Ph. D.</last_name>
    <phone>86-751-8120167</phone>
    <email>guohh1999@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Peiwen Zhang, M. D.</last_name>
    <email>313743920@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shaoguan University</name>
      <address>
        <city>Shaoguan</city>
        <state>Guangdong</state>
        <zip>512005</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peiwen Zhang, M. D.</last_name>
      <phone>86-18318540744</phone>
      <email>313743920@qq.com</email>
    </contact>
    <contact_backup>
      <last_name>Di Li, M. D.</last_name>
      <phone>86-15820231739</phone>
      <email>626800557@qq.com</email>
    </contact_backup>
    <investigator>
      <last_name>Peiwen Zhang, M. D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Honghui Guo, Ph. D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 8, 2014</lastchanged_date>
  <firstreceived_date>September 2, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>oxidative stress</keyword>
  <keyword>dyslipidemia</keyword>
  <keyword>inflammation</keyword>
  <keyword>apoptosis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
